Updated Jul 16, 2026
Audhya Paul K. has filed 5 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $520K.
Paul K. Audhya is the Chief Medical Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to his role within the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | KALV | KalVista Pharmaceuticals, Inc. | D — Derivative transaction | 150.3K | $0.00 | |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.2K | $26.78 | $60K |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.7K | $26.78 | $72K |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.0K | $26.76 | $28K |
| 2026-05-19 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 2.4K | — | |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.7K | $20.22 | $54K |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 5.4K | $15.57 | $83K |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.2K | $15.00 | $17K |
| 2026-02-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 2.4K | — | |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.3K | $13.42 | $31K |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.9K | $13.22 | $39K |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2025-08-17 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 2.9K | $13.19 | $39K |
| 2025-08-17 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.4K | — |
Paul K. Audhya is the Chief Medical Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. He has been involved in multiple SEC filings related to his role within the company.…
5 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($520K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Audhya Paul K. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.